- Market Capitalization, $K 121,962
- Shares Outstanding, K 17,883
- Annual Sales, $ 27,630 K
- Annual Income, $ -13,620 K
- 60-Month Beta -0.27
- Price/Sales 4.37
- Price/Cash Flow N/A
- Price/Book 1.09
|Period||Period Low||Period High||Performance|
| || |
-1.77 (-20.61%)since 03/12/21
| || |
-0.57 (-7.71%)since 01/14/21
| || |
-8.88 (-56.56%)since 04/14/20
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications Program initially targeting vascular Ehlers-Danlos Syndrome...
Zacks.com featured highlights include: Avid Bioservices, Oncternal Therapeutics, Amtech Systems and Aytu Biopharma
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.
ENGLEWOOD, CO / ACCESSWIRE / April 5, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today...
Strategic Transaction Provides $7.5M in Non-Dilutive Capital and Enables Pediatric and ADHD Product Focus Following the Recently Closed Merger with Neos Therapeutics
$100M revenue specialty pharmaceutical company on an accelerated path to profitability Company name change to Aytu BioPharma, Inc. becomes effective today Former Neos Therapeutics board members Beth...
Aytu Bioscience, Inc. (AYTU) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near...
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INOV, OPGN, SFT, SURF, and AYTU.
Data indicate endotracheal UVA light catheter therapy reduces SARS-CoV-2 viral load and improves clinical outcomes in mechanically ventilated SARS-CoV-2 patients
ENGLEWOOD, CO / ACCESSWIRE / February 24, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs,...